​

Sutro Biopharma (STRO) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChart

STRO Stock Forecast

Sutro Biopharma (STRO) stock forecast, based on 18 Wall Street analysts, predicts a 12-month average price target of $9.86, with a high of $15.00 and a low of $2.00. This represents a 750.00% increase from the last price of $1.16.

- $3 $6 $9 $12 $15 High: $15 Avg: $9.86 Low: $2 Last Closed Price: $1.16

STRO Stock Rating

Sutro Biopharma stock's rating consensus is Buy, based on 18 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 13 Buy (72.22%), 4 Hold (22.22%), 1 Sell (5.56%), and 0 Strong Sell (0.00%).

Buy
Total 18 0 1 4 13 Strong Sell Sell Hold Buy Strong Buy

STRO Price Target Upside V Benchmarks

TypeNameUpside
StockSutro Biopharma750.00%
SectorHealthcare Stocks 15.45%
IndustryBiotech Stocks 41.48%

Price Target Trends

1M3M12M
# Anlaysts--1
Avg Price Target--$2.00
Last Closing Price$1.16$1.16$1.16
Upside/Downside--72.41%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Oct, 25144-110
Sep, 25144-110
Aug, 25143-19
Jul, 25144-110
Jun, 25-45-110
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Mar 14, 2025Piper Sandler$2.00$0.81146.91%72.41%
Oct 11, 2024Tazeen AhmadBank of America Securities$12.00$3.61232.41%934.48%
Oct 11, 2024Andrew FeinH.C. Wainwright$12.00$3.61232.41%934.48%
Aug 16, 2024Asthika GoonewardeneTruist Financial$15.00$4.21256.29%1193.10%
May 14, 2024James ShinDeutsche Bank$10.00$4.34130.41%762.07%
May 14, 2024David NierengartenWedbush$8.00$4.2389.13%589.66%
Apr 03, 2024Jay OlsonOppenheimer$10.00$5.0996.46%762.07%
Apr 03, 2024Edward TenthoffPiper Sandler$11.00$5.09116.11%848.28%
Apr 02, 2024Asthika GoonewardeneTruist Financial$18.00$5.09253.63%1451.72%
Jan 13, 2023Truist Financial$25.00$8.14207.13%2055.17%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Jun 15, 2025Piper SandlerOverweightOverweightupgrade
Oct 11, 2024H.C. WainwrightUnderperformUnderperformhold
Oct 11, 2024Piper SandlerOverweightOverweighthold
Oct 11, 2024Bank of America SecuritiesBuyBuyhold
Oct 11, 2024H.C. WainwrightBuyBuyhold
Sep 16, 2024JMP SecuritiesMarket OutperformMarket Outperformhold
Sep 16, 2024Cowen & Co.BuyBuyhold
Aug 14, 2024Cowen & Co.BuyBuyhold
Aug 14, 2024Piper SandlerOverweightOverweighthold
May 14, 2024Deutsche BankBuyBuyhold

Financial Forecast

EPS Forecast

$-5 $-4 $-3 $-2 $-1 $0 $1 Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-1.11$-2.36$-2.35$-1.78$-2.96----
Avg Forecast$0.08$-2.23$-2.51$-2.53$-2.90$-3.04$-2.87$-2.51$-1.87
High Forecast$0.13$-1.03$-1.36$-2.40$-2.41$-2.07$-1.74$-0.93$-0.66
Low Forecast$0.04$-3.46$-4.31$-2.62$-3.22$-3.84$-4.33$-3.74$-3.99
Surprise %-1487.50%5.83%-6.37%-29.64%2.07%----

Revenue Forecast

$0 $80M $160M $240M $320M $400M Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$42.72M$61.88M$67.77M$153.73M$62.04M----
Avg Forecast$42.67M$62.36M$68.38M$97.35M$59.04M$49.16M$45.94M$145.60M$206.38M
High Forecast$60.69M$88.71M$106.16M$110.25M$70.66M$92.27M$45.94M$273.24M$387.31M
Low Forecast$25.04M$36.60M$44.31M$85.87M$49.61M$24.77M$45.94M$73.37M$104.00M
Surprise %0.13%-0.77%-0.89%57.91%5.08%----

Net Income Forecast

$-300M $-230M $-160M $-90M $-20M $50M Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-36.20M$-108.67M$-119.20M$-106.79M$-227.46M----
Avg Forecast$4.96M$-97.97M$-112.81M$-106.79M$-169.29M$-177.93M$-182.59M$-140.51M$-112.27M
High Forecast$7.69M$-78.38M$-90.25M$-85.43M$-145.10M$-124.61M$-104.68M$-55.81M$-39.86M
Low Forecast$2.30M$-117.57M$-135.37M$-128.15M$-193.47M$-231.25M$-260.50M$-225.20M$-240.22M
Surprise %-829.43%10.92%5.67%-34.36%----

STRO Forecast FAQ

Is Sutro Biopharma stock a buy?

Sutro Biopharma stock has a consensus rating of Buy, based on 18 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 13 Buy, 4 Hold, 1 Sell, and 0 Strong Sell, reflecting a consensus that Sutro Biopharma is a favorable investment for most analysts.

What is Sutro Biopharma's price target?

Sutro Biopharma's price target, set by 18 Wall Street analysts, averages $9.86 over the next 12 months. The price target range spans from $2 at the low end to $15 at the high end, suggesting a potential 750.00% change from the previous closing price of $1.16.

How does Sutro Biopharma stock forecast compare to its benchmarks?

Sutro Biopharma's stock forecast shows a 750.00% upside, outperforming the average forecast for the healthcare stocks sector (15.45%) and outperforming the biotech stocks industry (41.48%).

What is the breakdown of analyst ratings for Sutro Biopharma over the past three months?

  • October 2025: 10.00% Strong Buy, 40.00% Buy, 40.00% Hold, 0% Sell, 10.00% Strong Sell.
  • September 2025: 10.00% Strong Buy, 40.00% Buy, 40.00% Hold, 0% Sell, 10.00% Strong Sell.
  • August 2025: 11.11% Strong Buy, 44.44% Buy, 33.33% Hold, 0% Sell, 11.11% Strong Sell.

What is Sutro Biopharma’s EPS forecast?

Sutro Biopharma's average annual EPS forecast for its fiscal year ending in December 2025 is $-3.04, marking a 2.70% increase from the reported $-2.96 in 2024. Estimates for the following years are $-2.87 in 2026, $-2.51 in 2027, and $-1.87 in 2028.

What is Sutro Biopharma’s revenue forecast?

Sutro Biopharma's average annual revenue forecast for its fiscal year ending in December 2025 is $49.16M, reflecting a -20.76% decrease from the reported $62.04M in 2024. The forecast for 2026 is $45.94M, followed by $145.6M for 2027, and $206.38M for 2028.

What is Sutro Biopharma’s net income forecast?

Sutro Biopharma's net income forecast for the fiscal year ending in December 2025 stands at $-178M, representing a -21.77% decrease from the reported $-227M in 2024. Projections indicate $-183M in 2026, $-141M in 2027, and $-112M in 2028.